p95HER2 fragments resulting from the proteolytic cleavage of the HER2 ECD have generated much interest due to the association of the 100–115 kDa p95HER2 fragment with a clinically more aggressive subset of HER2-positive breast cancers [4]. The gene discussed is ERBB2; the disease is breast cancer.